Trandolapril Production Cost Reports

The report provides a detailed analysis essential for establishing a Trandolapril production plant. It encompasses all critical aspects necessary for Trandolapril production, including the cost of Trandolapril production, Trandolapril plant cost, Trandolapril production costs, and the overall Trandolapril production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Trandolapril production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Trandolapril is an angiotensin-converting enzyme (ACE) inhibitor that is available as oral tablets. It is used for treating high blood pressure (hypertension) by relaxing blood vessels to ease the heart's workload. It lowers the risks of strokes, heart attacks, and kidney problems, while also proving effective in post-heart attack care for patients with stable heart failure or left ventricular dysfunction.

It boosts survival rates, cuts hospitalisations and improves pumping efficiency by reducing strain on weakened cardiac muscle. It is used as monotherapy or alongside diuretics and other antihypertensives for mild to moderate hypertension management. It is also utilised in adjunct therapy in congestive heart failure to support heart function and curb disease progression, and to slow renal damage in hypertensive diabetics.

The market for Trandolapril is driven by growing global hypertension cases. The rise in ageing populations, urbanisation, lifestyle shifts, and heightened cardiovascular awareness contributes to its demand. The rising heart failure incidence, particularly post-heart attacks, expanding use in renal protection for diabetics, and sustained demand within the broader ACE inhibitor segment make it a popular drug.

The generic competition post-patent expiry, exerting pricing pressures and supply disruptions from production delays or unexpected demand surges, affects industrial Trandolapril procurement. Other factors like overreliance on limited API suppliers, vulnerable to geopolitical tensions and raw material fluctuations and strict regulatory compliance for DMFs and pharmacopeial standards impact its sourcing.

Raw Material for Trandolapril Production

According to the Trandolapril production plant project report, the key raw materials used in the production of Trandolapril include L-Pyroglutamic Acid and Allyl-TMS.

Production Process of Trandolapril

The extensive Trandolapril production cost report consists of the following major industrial production process:

1. From L-Pyroglutamic Acid: The production process of Trandolapril involves a multi-step stereoselective route. The process starts from protected L-pyroglutamic acid, followed by constructing the enantiopure octahydroindole core through α-allylation. After that, a highly diastereoselective Hosomi–Sakurai reaction and Ru-catalysed ring-closing metathesis take place. This is followed by conversion to the final ACE inhibitor via peptide coupling, to get Trandolapril as the final product.

Trandolapril is an ACE inhibitor prodrug that appears as a white or almost white crystalline powder with a bitter taste and no odour. It has a molecular formula of C24H34N2O5 and a molecular weight of 430.54 g/mol. It has a melting point at 119-125 degree Celsius. It is highly soluble in chloroform, dichloromethane, and methanol, with a logP value of 3.5, making it lipophilic.  It has a pKa value of around 5.21 (basic) with two hydrogen bond donors, five acceptors, and a polar surface area of 95.94 Ų. It is made up of a bicyclic octahydroindole core linked via peptide to an alanine-phenylbutyrate ethyl ester.